Cite

HARVARD Citation

    Hollebecque, A. et al. (2022). Clinical activity of CC‐90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 128 (17), pp. 3185-3195. [Online]. 
  
Back to record